Angelini Ventures Joins $39M Series A Extension for Therini Bio
Slice of Healthcare Team
05/22/2025
Key highlights
- Angelini Ventures participates in Therini Bio’s $39M Series A extension, bringing the round total to $75M.
- Therini Bio develops fibrin-targeting immunotherapies for Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME).
- Investment to fund Phase 1b trials of THN391 and development of a fibrin/VEGF bispecific candidate.
- Angelini Ventures builds on recent CNS-focused investments in Neumirna and Arclight.
- Fabrizio Calisti joins Therini Bio’s Board as Observer, enhancing strategic alignment.
Notable Quotes
“ We are proud to support Therini Bio’s mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. ”
Thomas Thestrup, Ph.D., Senior Principal at Angelini Ventures
“ We are deeply grateful to partner with such a distinguished investor group, both new and old. ”
Tara Nickerson, Ph.D., CEO at Therini Bio
Why This Matters
This strategic investment reflects growing momentum around novel therapies targeting the root causes of neurodegenerative diseases. Angelini Ventures' continued support of cutting-edge biotech innovations like Therini Bio underscores the increasing importance of targeting vascular dysfunction and neuroinflammation in diseases such as Alzheimer’s and DME. The Phase 1b advancement of THN391 could mark a pivotal step forward in developing disease-modifying treatments for CNS disorders, aligning with Angelini Ventures’ mission to back transformative healthcare solutions.
